Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy

Plain-language summary

This study investigated, through tissue biopsies, how tumors escape the immune system in patients with metastatic cancer that progressed during cancer immunotherapy (checkpoint inhibitor, CPI). It enrolled patients who had previously responded to immunotherapy but whose disease later progressed and from whom a tissue sample was available. The trial was conducted in Phase 4 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 4

Status

Completed

Sponsor

Hoffmann-La Roche

Intervention

Biopsy

Start date

2/16/2018

Estimated completion

8/4/2022

Countries

United States, France, South Korea, Spain, United Kingdom

Related genes

Locations

• San Francisco, United States
• Boston, United States
• St Louis, United States
• New York, United States
• Arrington, United States
• Toulouse, France
• Seoul, South Korea
• Seoul, South Korea
• Pamplona, Spain
• Barcelona, Spain
• London, United Kingdom

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Response assessment of complete response (CR), partial response (PR), or long-term stable disease (SD) for \>6 months with a cancer immunotherapy treatment for metastatic cancer or hematologic malignancies either through a marketed CPI or through participation in a Roche/Genentech CPI clinical trial.
* Availability of tissue sample.

Exclusion Criteria:

* Pregnant, lactating, or intending to become pregnant during the study.
* Participants receiving CPI treatment as part of a non-Roche/Genentech clinical trial.